Discuss LL-37 on glp1chat
Join the forum to discuss research with other members.
At a glance
LL-37 is part of the body's first line of defense against microbes. It can disturb microbial membranes and also change immune signals around injured tissue. Its effects vary with the concentration and location, so more immune activity is not always better.
LL-37 can damage the outer covering of some microbes, which is one way the body protects itself at a surface such as skin. It also signals to nearby immune cells during injury and repair. Those two actions explain why wound and infection models study it. Its effects can change with dose and tissue, however; a stronger immune signal can sometimes add inflammation rather than help.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses antimicrobial experiments and formulation-specific wound studies. Local wound findings should be separated from proposed systemic schedules.[3][4][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of LL-37.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (µg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 50 µg | 3 units (0.03 mL) |
| Week 2 | 100 µg | 6 units (0.06 mL) |
| Week 3 | 150 µg | 9 units (0.09 mL) |
| Week 4 | 200 µg | 12 units (0.12 mL) |
| Week 5 | 250 µg | 15 units (0.15 mL) |
| Week 6 | 300 µg | 18 units (0.18 mL) |
| Week 7 | 350 µg | 21 units (0.21 mL) |
| Week 8 | 400 µg | 24 units (0.24 mL) |
Frequency: Inject once daily subcutaneously. Some protocols use a 5-days-on, 2-days-off schedule. For ≤10-unit (≤0.10 mL) administrations during early titration, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support antimicrobial defense and wound-healing processes[3][4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 50–400 µg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 50–100 µg daily; increase by ~50 µg each week as tolerated.
- Target: 200–400 µg daily by Weeks 4–8.
- Frequency: Once per day (subcutaneous); optional 5-on/2-off schedule.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality[6][5].
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable ~24 months.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks; frozen at −20 °C (−4 °F) for up to 6 months.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[9].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
- Rotate sites systematically (abdomen, thighs, upper arms) and move at least 2–3 cm from the previous site[7].
- Use aseptic technique; always use a new sterile needle and syringe for each injection[6].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (LL-37, 5 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 5 vials
- 16 weeks ≈ 7 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- 16 weeks (7 vials): 21 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
Journal of Immunology (PMC) — Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 02
- 05
Source document
Bachem Knowledge Center — Handling and storage guidelines for peptides (opens in a new tab)www.bachem.com
Back to overview ↑ - 06
Public health resource
CDC One & Only Campaign — One needle, one syringe, only one time (injection safety) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 07
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (site selection, rotation) (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 08
Research publication
PubMed / Journal of Steroid Biochemistry — Vitamin D and the antimicrobial peptide cathelicidin (LL-37) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
MedlinePlus (NIH) — Subcutaneous (SQ) injections: patient instructions (opens in a new tab)medlineplus.gov
Back to overview ↑ - 10
Public health resource
CDC — Vaccine administration: subcutaneous injection (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Research publication
Clinical Pharmacology & Therapeutics (PMC) — Subcutaneous drug injection review: pharmacologic considerations (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑